October 2, 2025
After rising share pricing from a traumatic Wednesday; the cell and gene therapy sector wobbles
I also hate to be negative or a hardened contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but, I am mostly EARLY!”
Pre-open Signals: 6 Positive, 2 Sell into Strength and 3 Negative Indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
September 29, 2025
For gross proceeds of $345 M
QURE closed up +$5.09 or +9.37% to $59.40 with an aftermarket pricing of -$1.25 or -2.10% to $58.15
QURE had soared by 291% week-on-week to climb to a new all-time high based on astronomical performance of its delivered gene therapy treatment AMT-130 for Huntington’s disease.
October 2, 2025
Government’s 2nd day “turn-off”, a “normal” market and sector mixed forward
As we celebrate observance of Yom Kippur
We seem to be always waiting for … something i.ie., anything!
Reiterating, “uncle algo and his electronic trading dwarfs” are scheming to sell some
Never leave an investor uninformed!
September 29, 2025
For gross proceeds of $345 M QURE closed up +$5.09 or +9.37% to $59.40 with an aftermarket pricing of -$1.25 or -2.10% to $58.15 QURE had soared by 291% week-on-week to climb to a new all-time high based on astronomical performance of its delivered gene therapy treatment AMT-130 for Huntington’s disease.
September 22, 2025
Who is pumping the volume thus the price, after the usual small and inching volume or no volume is "suddenly" elevated 3506 shares trading (don't forget dive by half for buys and sells) - thus the pump. Challenging and questionable "aspects" of today, Monday's (9/22) state the obvious – a Ponzi Scheme! They’re BROKE filing with yet another PPM unfulfilled! What valuation model would even/ever justify a PPM pricing? Accumulated deficit to date= $103.2 M WHO is their major shareholder – DST Capital and itsDAILY buyer, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. ??? U.S. investors BEWARE, forewarned is forearmed?
September 15, 2025
Roche (RHO-DE: XETRA) confirmed it is staying put for now after fallout from drug pricing negotiations that saw the nation’s health minister walk away from talks. Merck (MRK) is moving all R&D operations out of UK, Eli Lilly (LLY) is pausing the build-out of UK biotech incubator,
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
